Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

31.59
-0.4300-1.34%
Post-market: 31.770.1800+0.57%17:55 EDT
Volume:1.70M
Turnover:54.17M
Market Cap:5.48B
PE:-14.62
High:32.57
Open:32.02
Low:31.52
Close:32.02
52wk High:43.73
52wk Low:13.78
Shares:173.52M
Float Shares:166.83M
Volume Ratio:0.74
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:11.72
PE(LYR):-12.39

Loading ...

Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027

Reuters
·
Aug 11

Harrow Q2 Revenue Slightly Beats Estimates

Reuters
·
Aug 11

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Reuters
·
Aug 11

Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending

Reuters
·
Aug 11

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

Reuters
·
Aug 11

Septerna Q2 Revenue Beats Analyst Estimates, Driven by Novo Nordisk Partnership

Reuters
·
Aug 11

Cogent Biosciences Q2 Loss Widens

MT Newswires Live
·
Aug 10

Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss

MT Newswires Live
·
Aug 10

Cogent Biosciences Q2 Net Income USD -96.405 Million

Reuters
·
Aug 10

Cogent Biosciences Q2 Operating Expenses USD 102.638 Million

THOMSON REUTERS
·
Aug 10

Cogent Biosciences - Submits Nda to FDA for Bezuclastinib in Advanced Systemic Mastocytosis

THOMSON REUTERS
·
Jun 30

Cogent Biosciences Submits FDA NDA for Bezuclastinib in Advanced Systemic Mastocytosis

Reuters
·
Jun 30

Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base

Simply Wall St.
·
Jun 30

H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Jun 17

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Jun 15

Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed

Simply Wall St.
·
Jun 13

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

MT Newswires Live
·
Jun 12

Cogent Biosciences - Bezuclastinib Continues to Show Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 12

Cogent Biosciences - to Submit Apex Nda in June 2026

THOMSON REUTERS
·
Jun 12